Trial Condition(s):

Bronchiectasis, Pulmonary Disease, Chronic Obstructive

Summative Usability Study of Ciprofloxacin Dry Powder for Inhalation Using Placebo

Bayer Identifier:

18253

ClinicalTrials.gov Identifier:

NCT02661438

EudraCT Number:

Not Available

Study Completed

Trial Purpose

The rationale of this study is to conduct a summative (i.e., validation) usability test of Ciprofloxacin Dry Powder for Inhalation (DPI) and the associated Instructions for Use.

Inclusion Criteria
No Inclusion Criteria Available
Exclusion Criteria
Inclusion Criteria
- Subjects (male and female) with non-cystic fibrosis bronchiectasis (NCFB) or chronic obstructive pulmonary disease (COPD) 
- Subjects must be aged ≥40 
- Subject must be able to independently manage and administer their NCFB/COPD medications 


- Subjects with recent exacerbation 
- Subjects with recent significant hemoptysis in the four weeks before screening (and/or during the screening period)
- Subjects allergic to quinine 
- Known chronic bronchial asthma

Trial Summary

Enrollment Goal
46
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
Yes
Products
Unspecified
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Vero Beach, United States, 32960

Status
Completed
 
Locations

Investigative Site

Jamaica, United States, 11435

Status
Completed
 

Trial Design